SWOBY (Swedish Orphan Biovitrum AB) Other Long Term Assets: $267 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $23.50
GF Value $18.40
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Other Long Term Assets?

Swedish Orphan Biovitrum AB SWOBY -6.00% 67 Other Long Term Assets is $267 Mil as of Jun. 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Swedish Orphan Biovitrum AB's other long-term assets for the quarter that ended in Jun. 2026 was $267 Mil.

Swedish Orphan Biovitrum AB's quarterly other long-term assets increased from Dec. 2025 ($236 Mil) to Mar. 2026 ($266 Mil) and increased from Mar. 2026 ($266 Mil) to Jun. 2026 ($267 Mil).

Swedish Orphan Biovitrum AB's annual other long-term assets increased from Dec. 2023 ($96 Mil) to Dec. 2024 ($157 Mil) and increased from Dec. 2024 ($157 Mil) to Dec. 2025 ($236 Mil).

Swedish Orphan Biovitrum AB Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Other Long Term Assets Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.39 96.26 96.03 157.31 236.19

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138.77 145.74 236.19 266.39 266.83
SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $267 Mil mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Other Long Term Assets of $267 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Other Long Term Assets too high?
Swedish Orphan Biovitrum AB's current Other Long Term Assets is $267 Mil. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Other Long Term Assets compare to ZTS?
Swedish Orphan Biovitrum AB's Other Long Term Assets of $267 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Other Long Term Assets is $267 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current Other Long Term Assets is $267 Mil. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Other Long Term Assets is $267 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for SWOBY:

  • Other Long Term Assets: $267 Mil
  • GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.50
Price
$18.40
GF Value